BlossomHill Therapeutics (BLSM) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CorMedix is the larger company by market cap ($570.6 million vs $536.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | CRMD |
|---|---|---|
| Share price | $16.88 | $7.32 |
| Market cap | $536.53M | $570.55M |
| 1-day change | +1.63% | +0.55% |
| YTD return | — | -37.06% |
| 1-year return | — | -35.05% |
| 5-year return | — | +47.88% |
| P/E ratio (TTM) | — | 3.57 |
| Forward P/E | — | 20.91 |
| EPS (TTM) | $-4.70 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $13.02 |
| 52-week low | $15.25 | $6.13 |
| Distance from 52-week high | -39.69% | -43.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +109.72% | +109.43% |
| Average volume | 261.23K | 1.06M |
| Shares outstanding | 31.78M | 77.94M |
| Employees | 69 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
BLSM vs CRMD FAQ
Which is bigger, BlossomHill Therapeutics or CorMedix?
CorMedix (CRMD) is larger, with a market capitalization of $570.55M compared with $536.53M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.